Congress Wealth Management’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-1,500
Closed -$17.9K – 714
2024
Q1
$17.9K Hold
1,500
– – ﹤0.01% 576
2023
Q4
$6.03K Hold
1,500
– – ﹤0.01% 606
2023
Q3
$4.11K Hold
1,500
– – ﹤0.01% 599
2023
Q2
$10K Buy
+1,500
New +$9.11K ﹤0.01% 551

Other funds holding CATX

Congress Wealth Management's CATX Position: Q2 2024 in Review

Congress Wealth Management sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 1,500 shares — an estimated $17.9K sold.

Congress Wealth Management first reported a position in CATX in Q2 2023 and held it in 4 quarters. The position peaked at $17.9K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Congress Wealth Management reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Congress Wealth Management sold 1,500 Perspective Therapeutics shares in Q2 2024, an estimated $17.9K.
  • Congress Wealth Management first reported a position in Perspective Therapeutics in Q2 2023 and held it in 4 quarters.
  • Congress Wealth Management's Perspective Therapeutics position peaked at $17.9K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Congress Wealth Management's 13F filing for Q2 2024, filed 14 Aug 2024.